Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCB099280 + Ipilimumab in Select Solid Tumors
NCT05909995Phase 1Terminated
- Sponsor
- Incyte
- Start
- Aug 2023
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of incb099280 in melanoma, hepatocellular carcinoma (HCC), renal cell carcinoma (RCC) and 1 more (2 arms), sponsored by Incyte. Primary endpoints: Occurrence of Dose-Limiting Toxicities at 2 Years, Incidence of Treatment-Emergent Adverse Events at 2 Years and 1 more. Started Aug 2023; status: terminated.
02
Drugs
incb099280
03
Conditions
melanomahepatocellular carcinoma (HCC)renal cell carcinoma (RCC)colorectal carcinoma (CRC)
Beyond the preview
Go deeper on NCT05909995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05909995.